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Abstract
Background Wilson disease requires lifelong therapy,
currently given daily in multiple divided dosages.
Aim To prospectively evaluate once-daily trientine as
therapy for Wilson disease.
Methods Study group: eight patients (seven males) aged
22–71 years with stable Wilson disease treated from 4 to
50 years. Patients were monitored for 3 months then for
12 months on a single daily dose of trientine (15 mg/kg).
Results All patients remained clinically well. ALT and
AST fluctuated in some, but none required treatment
stoppages or side effects. Liver synthetic function was
unchanged. Mean 24-h urine copper and zinc excretions at
end of treatment were 313.4 ± 191.7 and 2,214 ±
1,346 lg, respectively.
Conclusions Once-daily trientine should be explored
further for possible maintenance therapy for WD. Single
daily dose may improve adherence to therapy. Larger trials
and longer-term follow-up will establish the safety and
treatment efficacy of this once-daily treatment regimen for
WD (registration: NCT01472874).





INR International normalized ratio
WD Wilson disease
Introduction
Wilson disease (WD) is an autosomal recessive disorder of
copper metabolism affecting *1:30,000 individuals [1, 2].
Liver and neurological injury may be prevented or treated
by lifelong medical therapy with D-penicillamine or trien-
tine, or zinc salts that inhibit copper absorption. Up to
50 % of WD patients have medication non-adherence [3].
Failure to adhere to treatment inevitably leads to neuro-
logical injury and psychiatric symptoms, hepatic failure,
and ultimately death [4].
Trientine was approved for WD patients intolerant of D-
penicillamine [5, 6]. Trientine is gaining popularity as a
first-line agent due to its favorable safety profile. Trientine
is conventionally dosed at 750–1,500 mg/day in 2–4 divi-
ded doses. Increases in urinary trientine excretion correlate
with increased urinary copper excretion [7].
There have been very few prospective studies for treating
WD. Weiss et al. [8] retrospectively reviewed treatments for
WD, concluding that zinc was less effective than chelating
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agents for long-term use. They observed discontinuation for
treatment failure for 14/88 on zinc compared to 4/213 on
chelation therapy. Important factors such as having to
interrupt daily routines to avoid taking medications with
food is a significant lifestyle issue for some patients and
important for maintaining medication adherence [9].
Once-daily dose yields the highest compliance for drugs
with average tolerability; the more often a drug is taken, the
less the adherence [10, 11]. Adherence is better for drugs
perceived as having life and death consequence such as critical
antiarrhythmic therapy [12]. Drug adherence is more prob-
lematic for asymptomatic or stable conditions such as
hypertension or maintenance therapy for WD [13, 14]. Daily
dosed medications available as long-acting preparations are
frequently utilized in the treatment of chronic medical disor-
ders such as hypertension [15]. These daily dosed medications
had better adherence. There are currently no comparable
extended release preparations for treatments for WD.
There are few investigations of available chelators for
WD to inform about the frequency of their administration
[16]. Conventional recommendations are multiple daily
dosages administered apart from meals to enhance intesti-
nal absorption and maximize copper excretion. The
potential benefits of a once-daily trientine dose as main-
tenance therapy for WD were previously reported as a
retrospective review of case reports [17]. Three patients
took trientine once-daily for 2–15 years. Liver function and
parameters of copper metabolism were normal, and
examinations showed clinical stability. These data sug-
gested the need for a prospective trial. To this end, we
undertook a prospective study to determine the safety and
effectiveness of a 12-month course of a once-daily weight-
based dose of trientine for maintenance treatment for WD.
Methods
We designed a prospective study of once-daily trientine for
WD. The protocol was approved by the HIC committee at
Yale University Medical Center. The trial was registered
on www.clinicaltrials.gov (registration number
NCT01472874, first received: November 11, 2011, last
updated: July 17, 2012). Inclusion criteria required a
diagnosis of WD, [1 year clinical stability on current
therapy, and stable liver disease. The study group included
eight patients (seven males) aged 22–71 years treated from
4 to 50 years (median of 8 years). Presentations of WD
included asymptomatic (n = 1), incidental detection of KF
rings (n = 1), neuropsychiatric then liver and stable neu-
rological disease (n = 1), stable neurological with liver
disease (n = 1) and liver disease alone (n = 4). Prior
treatments were zinc acetate (n = 2), D-penicillamine
(n = 1), and trientine (n = 5). Patients were consented
before entry into the clinical trial. Three consecutive
monthly clinical and laboratory evaluations were made
before beginning the study treatment. The physical evalu-
ations included assessments of the neurological and liver
disease. Patients were asked to complete a pre- and post-
study questionnaire. Serum and 24-h basal urinary studies
prior to entry included blood counts with platelets, ALT,
AST, ALP, total bilirubin, direct bilirubin, gamma glut-
amyl transpeptidase, albumin, international normalized
ratio (INR), serum copper, serum ceruloplasmin, antinu-
clear antibody, erythrocyte sedimentation rate, 24-h urine
for copper and zinc excretion and volume, urinalysis, AST-
to-platelet ratio [18], and levels of several proteins
important for liver fibrosis [19]. Statistical testing of data
was performed using Student’s t test (two tailed) compared
mean values obtained before and after treatment.
Treatment was with trientine, 15 mg/kg (rounded upward
to the nearest 250 mg) once-daily for 12 months. Patients
were monitored monthly for 3 months and at 6, 9, and
12 months, and study coordinators reviewed patient logs and
conducted formal pill counts. Treatment dose was based on
AASLD practice guidelines and represents the dosage used
in children [1, 20, 21]. Subjects were to be removed from the
study if the laboratory values were abnormal (ALT or
AST[ twice baseline values) for two sequential blood tests
or for any decline in the patient’s health.
Results
After treatment with once-daily trientine, all were clini-
cally well. Their physical examination remained unchan-
ged, and no new neurological signs were detected. There
were no stoppages of treatment or dropouts from the study.
Liver Function Tests, Copper and Zinc Studies
Results for ALT, AST, total bilirubin, INR, albumin, serum
copper, 24-h urine copper and zinc are shown in Table 1. ALT
and AST levels were not statistically changed by treatment in
6/8 patients, and mean values were 41.38 ± 31.81 and
28.22 ± 10.57 U/L, respectively, on their prior therapy, and
50.89 ± 32.29 and 33.53 ± 11.17 U/L at trial end. In two
(patients 2 and 3), the differences in mean ALT before and
after treatment did reach statistical significance, but end of
treatment values were at the upper limit of normal in one and
above normal but\2 times the upper limit of normal in the
other. Neither had changes in hepatic synthetic function or
bilirubin over the course of treatment. Total bilirubin, albu-
min, and INR were relatively unchanged for the cohort at the
trial end. Urinary copper excretion increased from baseline
values from 2.8 to 9.5 times baseline values in patients
changed from pre-treatment zinc to trientine as expected, but
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Table 1 Biochemical testing before and after trientine treatment
Medication Pre-treatment Post-treatment p value
Mean ± SD Min–max Mean ± SD Min–max
ALT (0–35 U/L)
P1 Trientine 33.33 ± 4.04 31–38 58.66 ± 15.84 40–82 0.123
P2 D-Penicillamine 16.75 ± 2.21 14–19 34 ± 4.77 28–41 0.006
P3 Zinc 29.75 ± 5.56 26–38 52.67 ± 16.35 37–76 0.003
P4 Trientine 17.75 ± 2.5 15–21 22.17 ± 4.44 19–31 0.242
P5 Zinc 35.25 ± 23.64 17–69 19.2 ± 2.16 17–22 0.311
P6 Trientine 100.75 ± 30.99 58–132 116.16 ± 12.73 102–139 0.483
P7 Trientine 22.5 ± 2.08 20–25 26.67 ± 6.56 18–38 0.659
P8 Trientine 73 ± 13.68 57–89 72.33 ± 6.37 64–80 0.955
All 41.38 ± 31.81 14–132 50.89 ± 32.29 17–139 0.448
INR (0.8–1.15)
P1 Trientine 0.95 ± 0.03 0.93–0.99 1.05 ± 0.05 0.99–1.13 0.129
P2 D-Penicillamine 1.12 ± 0.05 1.05–1.17 1.24 ± 0.04 1.18–1.31 0.038
P3 Zinc 0.94 ± 0.02 0.93–0.95 1.04 ± 0.03 1.01–1.09 0.019
P4 Trientine 0.90 ± 0.02 0.88–0.94 0.96 ± 0.06 0.89–1.09 0.086
P5 Zinc 1.01 ± 0.05 0.98–1.1 1.03 ± 0.02 0.99–1.07 0.706
P6 Trientine 1 ± 0.04 0.96–1.05 1.03 ± 0.01 1.02–1.06 0.114
P7 Trientine 0.99 ± 0.04 0.95–1.05 1.04 ± 0.04 0.99–1.12 0.071
P8 Trientine 0.99 ± 0.02 0.95–1.01 1.02 ± 0.07 0.96–1.16 0.289
All 0.99 ± 0.07 0.93–1.17 1.05 ± 0.08 0.89–1.31 0.002
Cu serum (0.75–1.45 mcg/ml)
P1 Trientine 0.74 ± 0.07 0.66–0.81 0.79 ± 0.05 0.71–0.87 0.297
P2 D-Penicillamine 0.29 ± 0.01 0.27–0.31 0.26 ± 0.02 0.24–0.3 0.048
P3 Zinc 1.0 ± 0.07 0.94–1.1 0.88 ± 0.10 0.8–1.02 0.062
P4 Trientine 0.65 ± 0.04 0.6–0.7 0.66 ± 0.01 0.64–0.69 0.533
P5 Zinc 0.48 ± 0.59 0.4–0.53 0.43 ± 0.06 0.38–0.53 0.434
P6 Trientine 0.11 ± 0.02 \0.1–0.14 0.11 ± 0.008 0.11–0.13 0.634
P7 Trientine 0.80 ± 0.06 0.74–0.9 0.84 ± 0.02 0.82–0.85 0.474
P8 Trientine 0.16 ± 0.02 0.13–0.19 0.16 ± 0.009 0.15–0.18 0.717
All 0.54 ± 0.30 \0.1–1.1 0.52 ± 0.30 0.11–1.02 0.964
Cu urine (15–60 mcg/24 h)
P1 Trientine 144.3 ± 9 135–154 239.8 ± 90.3 150–411 0.301
P2 D-Penicillamine 843.5 ± 35.9 793–877 485.6 ± 276.4 131–833 0.084
P3 Zinc 181.7 ± 34.8 144–224 513.5 ± 166.4 267–684 0.033
P4 Trientine 60.2 ± 40.7 18–116 200 ± 33.5 155–234 0.028
P5 Zinc 10 ± 1.4 9 and 11 95.2 ± 20.5 66–122 0.052
P6 Trientine 327 ± 27.3 303–363 374 ± 113.9 203–476 0.625
P7 Trientine 227.6 ± 33.7 189–251 370.8 ± 86.6 227– 450 0.104
P8 Trientine 318.7 ± 154.4 135–507 211.8 ± 144.5 110–500 0.445
All 287.9 ± 259.1 9–877 313.4 ± 191.7 66–833 0.643
Zn urine (300–600 mcg/24)
P1 Trientine 1,109 ± 86 944–1,311 1,944 ± 1,110 820–2,917 0.442
P2 D-Penicillamine 3,297 ± 106 3,192–3,439 3,441 ± 1,645 1,481–5,228 0.855
P3 Zinc 1,990 ± 493 1,475–2,535 1,718 ± 799 727–3,091 0.969
P4 Trientine 1,598 ± 566 912–2,297 2,669 ± 642 1,986–3,671 0.155
P5 Zinc 656 ± 186 503–864 1,316 ± 209 963–1,461 0.113
P6 Trientine 1,482 ± 322 1,002–1,698 1,231 ± 461 498–1,759 0.432
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was relatively unchanged for patients on D-penicillamine or
trientine following their change to once-daily trientine. One
patient, patient 4, had a 330 % increase in copper excretion,
likely from better adherence. In line with the findings obtained
from urinary copper, the patients all had non-ceruloplasmin
copper that was below 15 mcg/dl prior to study entry and no
patient exceeded this threshold during the study. Mean 24-h
urine zinc excretion was not significantly changed after
treatment for the cohort, but there were two patients on tri-
entine that increased their zinc excretion by*40 % (Fig. 1).
Full Blood Count, ANA, and Dropout from the Study
Blood counts remained stable after therapy (data not
shown), and all had negative screens for antinuclear
antibodies before and after treatment. There was no patient
dropout from the trial, and no patients were removed from
the study for abnormal laboratory values or clinical evi-
dence of worsening disease.
Indirect Measures of Hepatic Fibrosis
The AST-to-platelet ratio did not change at treatment end
(data not shown), and similarly, serum markers associated
with fibrosis (that are also components of the FibrotestTM)
remained similar or improved from before to end of
treatment (see Table 2).
Questionnaires
Questionnaire results are shown in Table 3. Before the
study, three patients missed one dose/week; one each
missed 2, 4, and 5 doses/week, and two missed[5 doses/
week. At study end, all patients reported that the once-daily
dose of the trientine improved their ability to avoid missing
medication dosages and that it was easier and preferable to
take the medication once-daily.
Discussion
WD is treated with chelators to promote copper excretion,
or with zinc to reduce copper absorption. There is no
preferred treatment regimen given the lack of prospectively
controlled studies to estimate the relative treatment efficacy
or adherence to the available treatments for WD. Unfor-
tunately, the lifelong need for therapy and requirement for
Table 1 continued
Medication Pre-treatment Post-treatment p value
Mean ± SD Min–max Mean ± SD Min–max
P7 Trientine 3,607 ± 377 3,172–3,844 4,251 ± 784 2,892–4,837 0.405
P8 Trientine 1,805 ± 737 764–2,503 1,336 ± 1,054 691–3,453 0.644
All 1,959 ± 1,003 503–3,844 2,214 ± 1,346 498–5,228 0.428
Albumin (3.5–5.0 g/dL)
P1 Trientine 4.4 ± 0.2 4.2–4.6 4.53 ± 0.18 4.3–4.8 0.789
P2 D-Penicillamine 0.29 ± 0.01 0.27–0.31 0.26 ± 0.02 0.24–0.3 0.048
P3 Zinc 1.0 ± 0.07 0.94–1.1 0.88 ± 0.10 0.8–1.02 0.062
P4 Trientine 0.65 ± 0.04 0.6–0.7 0.66 ± 0.01 0.64–0.69 0.533
P5 Zinc 0.48 ± 0.59 0.4–0.53 0.43 ± 0.06 0.38–0.53 0.434
P6 Trientine 0.11 ± 0.02 0.1–0.14 0.11 ± 0.008 0.11–0.13 0.634
P7 Trientine 0.80 ± 0.06 0.74–0.9 0.84 ± 0.02 0.82–0.85 0.474
P8 Trientine 0.16 ± 0.02 0.13–0.19 0.16 ± 0.009 0.15–0.18 0.717
All 0.54 ± 0.30 0.1–1.1 0.52 ± 0.30 0.11–1.02 0.964
Bold values are statistically significant (p\ 0.05)
Fig. 1 The graph demonstrates the variation of ALT during the
period of the experimental study. Visits 1–4 were the pre-treatment
and baseline visits. With upper limit of normal at 40, only 3 were
above at the start. All the patients had end values below the 0 time
point at the end of the study except series 3 but that patient had a
value below 100 a year later
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multiple daily dose of medications has led to non-adher-
ence to treatment and clinical deterioration and death for
some WD patients, leading us to look for alternatives.
Trientine is increasingly recognized as first-line treat-
ment for WD due to fewer unwanted effects than D-peni-
cillamine. Pancytopenia occurs rarely, and hypersensitivity
Table 2 Serum fibrosis markers
Medication Alpha-2-macroglobulin Haptoglobin Apolipoprotein A1 GGT Total bilirubin ALT
Start End Start End Start End Start End Start End Start End
P1 Trientine 23 159 156 167 168 36 52 0.62 0.3 31 40
P2 D-Penicillamine 269 264 \6.0 \6.0 161 178 42 48 1.06 1.47 14 38
P3 Zinc 565 443 89.9 60 145 180 17 32 0.38 0.47 38 69
P4 Trientine 177 191 86 95.9 169 196 13 14 0.32 0.34 17 22
P5 Zinc 208 181 155 271 171 134 27 18 0.38 0.32 17 18
P6 Trientine 353 397 12.6 7.5 174 157 66 100 0.8 0.65 132 112
P7 Trientine 208 188 117 126 130 103 27 31 0.92 0.47 23 27
P8 Trientine 149 143 128 121 111 108 90 105 0.96 0.58 89 80
Units and ranges of normal for tests are as follows: alpha-2-macroglobulin: 131–293 mg/dL; haptogloblin: 20–200 mg/dL; apolipoprotein A1:
94–178 mg/dL; GGT: 11–55 U/L; total bilirubin:\1.2 mg/dL; ALT: 0–34 U/L
Table 3 Questionnaire responses at start and end of study
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8
Pre-treatment questionnaire
What medication are you taking for Wilson’s
disease?
Trientine D-Pen Zinc Trientine Zinc Trientine Trientine Trientine
How long have you been on this medication? 3 years 40 years 5 years 5.5 years 3 years 4.3 years 5 years 5.25 years
How many times per day do you take your
medication?
2 1 2 2 3 2 2 2
How many dosages of your medication are
taken 1 h before or 2 h after meals?
All All All All 1 All All All
How many dosages of your medication do you
miss in a week’s time?
1 1 [5 1 [5 2 5 4
What is the longest time you have gone without
your medication?
1 day 2 days 4 days 30 days 4 days 0 4 days 300 days
Does having to take the medication 1 h before
meals or 2 h after meals interfere with your
daily schedule?
Yes No No No Yes Yes No Yes
Do you think it will be easier for you to take
your medication as a single dosage?
Yes Yes Yes Yes Yes Yes Yes Yes
Post-treatment questionnaire
Did taking your medication as a single daily
dosage improve your ability to take the entire
daily amount of medication needed?
Yes Yes Yes No Yes Yes Yes Yes
Was taking your medication as a single daily
dosage less interfering with your daily
schedule?
Yes Yes Yes Yes Yes Yes Yes Yes
Would you prefer to take your medications as a
single daily dosage if your testing showed
that your Wilson disease was well controlled
during this trial?
Yes Yes Yes Yes Yes Yes Yes Yes
Which medication would you prefer to take for
your Wilson disease?
Zinc* Trientine Trientine Trientine Trientine Trientine Trientine** Trientine
* Financial consideration; ** whichever is ‘‘cheapest’’
Dig Dis Sci (2015) 60:1433–1439 1437
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reactions and renal effects have not been reported [22].
Neurological deterioration during initiation of therapy is
infrequent but recognized [23]. Therefore, we focused our
attention on this agent.
In this prospective pilot study, we evaluated once-daily
trientine for WD maintenance therapy. Our expectations of
continued clinical and laboratory stability were mostly
achieved. There were mild changes in serum aminotrans-
ferases in the group overall as reflected by the ranges noted
in Table 1, but liver function (INR, and albumin and total
bilirubin) remained mostly unchanged (Table 1). In two
(patients 2 and 3, Table 1) in whom ALT levels increased
slightly at study end, we found no obvious reason for this
observation. Their exams, weight, and hepatic synthetic
function remained intact. Patient 3 missed[5 doses a week
prior to the study, and his increased urine copper excretion
probably reflected consistent medication usage. In the
study group, there were two patients in whom past symp-
toms included neurological and psychiatric symptomatol-
ogy, but in one of these individuals the psychiatric
symptoms were resolved, and in both neurological symp-
toms were stable. Both had been maintained on therapy
with stable examinations prior to the study, as was a
requirement for inclusion in the study, and remained stable
throughout the study.
Urine copper excretion and serum copper were stable for
patients before and during the study (Table 1), including
the ‘‘free’’ non-ceruloplasmin copper and urinary copper.
The patients all had non-ceruloplasmin copper that was
below 15 mcg/dl prior to entry into the study, and no
patient exceeded this threshold during the study (data not
shown). Liver biopsies were not obtained, as they are not
routinely used to follow treatment in WD. However, AST-
to-platelet ratio and serum markers of fibrosis were not
changed at study end, indirectly suggesting no change in
hepatic fibrosis.
Zinc must be taken apart from meals for WD treatment
and is often administered thrice daily [24]. The normative
requirement for absorbed zinc is set at 1.4 mg/day for men
and 1.0 mg/day for women. All patients had elevated urine
excretion of zinc while on trientine. To our knowledge,
there is no evidence for zinc deficiency in WD patients on
therapy with trientine or D-penicillamine, likely due to the
ubiquitous presence of dietary zinc. Activity of alkaline
phosphatase, a zinc dependent enzyme, was not altered in
our patients who transitioned from zinc to trientine (data
not shown).
Patient questionnaires revealed a perceived advantage of
trientine given once-daily was the convenience of not
having to time dosages to 1 h before or 2 h after meals.
The once-daily regimen seemed to improve patient
adherence to treatment, in particularly in the two patients
who missed[5 doses/week before the study. Though we
cannot negate the effect of study enrollment on adherence
since patients had medication checks and periodic pill
counts, we hoped that once-daily treatment would improve
adherence beyond the study period.
We believe that once-daily weight-based dose of trien-
tine merits further study for long-term maintenance therapy
for WD. Of note, the pediatric weight-based dosage often
exceeds what is given to adults on a daily basis. The choice
of dose in adults is empiric and based on treatment expe-
rience of experts as there is a lack of evidence-based
comparative data on this subject. The weight-based dose
used in this study compared to the usual one-size fits all
dose deserves particular mention and highlights the need
for more formal studies to determine the proper dose of
these medications. In our cohort, the patients previously on
chelation therapy maintained similar 24-h urine copper
excretions in the study, suggesting the 15 mg/kg yields
adequate daily copper excretion. We do recognize the
limitation of having not studied more than one dosage, and
this can be addressed in future studies.
Since the study group was small in this pilot study, a
larger study group would be required to achieve statistical
significance to prove efficacy and bioequivalence. We
believe that the time to detect signal for treatment failure or
non-adherence is within 6 months based on prior studies of
adolescents who were non-adherent with treatment [8], and
is consistent with our personal experience with a large
number of patients with Wilson disease over the years.
Based on this, current recommendations are for bi-annual
monitoring of patients in maintenance therapy in both
AASLD and EASL guidelines [1, 26]. If we had seen lower
urine copper excretion, then this might lend credence to the
suggestion for potential for slow copper accumulation, but
it is important that we did not observe this at all. Therefore,
while longer periods of study are always wished for, we
believe our period of observation exceeded the minimum
needed to detect signal for treatment failure or non-
adherence.
Our observations suggest that a once-daily weight-based
dosage of trientine is an attractive regimen for WD patients
for maintenance therapy. A recent publication of from
Dzie _zyc et al. [25] reported improved survival rates for
asymptomatic patients adherent to therapy compared to
non-compliant patients, further strengthening the argument
that a simpler treatment regimen will benefit adherence.
Longer-term follow-up of our patients and others on once-
daily therapy is needed to establish its safety and treatment
efficacy, with promising implications for the future man-
agement of patients with WD.
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